EUVIMEDEUVIMED entdecken
Crossref

Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey

Murat Sayan iD, Nazife Sultanoglu, Tamer Sanlidag

AIDS Research and Human Retroviruses · 2023

DOI: 10.1089/aid.2022.0065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, 2023. Verfasst von Murat Sayan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, PCR Unit, Kocaeli University, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV Seropositivity, HIV-1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rilpivirine, one of the non-nucleoside reverse transcriptase inhibitors class anti-HIV agents, is used as an alternative drug to treat HIV-1-positive individuals according to current antiretroviral therapy (ART) guidelines. Mutation in the position E138 in HIV-1 reverse transcriptase (RT) leads to resistance to rilpivirine, alone reducing its susceptibility two to threefolds. The main aim of this study was to determine the dynamics of E138 mutation in the RT domain of the HIV-1 pol gene; in 6398 newly diagnosed and treatment-naive individuals in Turkey from 2013 to 2021. Rilpivirine-associated mutations were found among 424 (6.6%) out of 6398. Individuals with the E138 mutation had significantly higher HIV-1 RNA load than individuals without the E138 mutation ( p = .044). The E138 mutation was mainly observed in the B subtype (40%) of HIV-1 compared to the non-B subtypes (26.9%) and the circulating recombinant forms (33.1%) ( p < .001). Most E138 mutations were E138A (80%), followed by E138G (16.5%). This study uncovered the dynamics of rilpivirine-associated mutations over a long period and a large patient population. Before administering ART regimens consisting of rilpivirine, resistance monitoring is highly recommended for effective patient management in the treatment—of naive HIV-1-infected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV SeropositivityHIV-1HumansAnti-Retroviral AgentsDrug Resistance, ViralMutationReverse Transcriptase InhibitorsRilpivirineTurkeyHIV Reverse Transcriptase

Stichwörter der Autor:innen

HIV-1drug resistancemutationrilpivirinesequence analysis

Substanzen

Anti-HIV AgentsAnti-Retroviral AgentsReverse Transcriptase InhibitorsRilpivirinereverse transcriptase, Human immunodeficiency virus 1HIV Reverse Transcriptase

Autor:innen und Institutionen

  • Clinical Laboratory, PCR Unit, Kocaeli University, Kocaeli, Turkey.
  • DESAM Research Institute, Near East University, Nicosia, North Cyprus.
  • Operational Research Center in Healthcare, Near East University, Nicosia, North Cyprus.
  • Department of Microbiology and Clinical Microbiology, Faculty of Medicine, Near East University, Nicosia, North Cyprus.

ORCID-Profile: Murat Sayan

Zitieren

APA

Sayan, M., Sultanoglu, N., & Sanlidag, T. (2023). Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2022.0065

Vancouver

Sayan M, Sultanoglu N, Sanlidag T. Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey. AIDS Research and Human Retroviruses. 2023. doi:10.1089/aid.2022.0065

BibTeX
@article{Sayan2023,
  author = {Sayan, Murat and Sultanoglu, Nazife and Sanlidag, Tamer},
  title = {Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey},
  journal = {AIDS Research and Human Retroviruses},
  year = {2023},
  doi = {10.1089/aid.2022.0065}
}
Kostenlos starten →